| Abul Ansari, | |
|
456 Daniel Webster Hwy, Merrimack, NH 03054-3699 | |
| (603) 424-1120 | |
| Not Available |
| Full Name | Abul Ansari |
|---|---|
| Gender | Male |
| Speciality | Pharmacist |
| Location | 456 Daniel Webster Hwy, Merrimack, New Hampshire |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1437509668 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 3810 (New Hampshire) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Abul Ansari, 456 Daniel Webster Hwy, Merrimack, NH 03054-3699 Ph: (603) 424-1120 | Abul Ansari, 456 Daniel Webster Hwy, Merrimack, NH 03054-3699 Ph: (603) 424-1120 |
News Archive
Reproductive researchers from the University of Pennsylvania and The Children's Hospital of Philadelphia have succeeded in isolating and transplanting pure populations of the immature cells that enable male reproduction in two species-human spermatogonia and mouse gonocytes. These germline stem cells, taken from testis biopsies, demonstrated viability following transplantation to mouse testes within a controlled laboratory setting.
Targeted Genetics Corporation announced that its partner, Celladon Corporation, presented full data today that show the first Phase II trial with MYDICAR® for the treatment of advanced heart failure has met its primary safety and efficacy endpoints, as prospectively defined in the Phase II trial protocol.
Alcohol treatment has come a long way from enforced isolation in asylums, and technological advancements are particularly promising in terms of their capacity to improve treatment effectiveness.
Celera Corporation today announced that it has signed a Declaration of Conformity and applied the CE mark to a real-time PCR (polymerase chain reaction) test for detection of a variant in the KIF6 gene, allowing the test to be marketed in the European Union and other geographic areas that recognize the CE Mark.
Some of the most effective and expensive cancer drugs, dubbed "smart drugs" for their ability to stop tumors by targeting key drivers of cancer cell growth, are not effective in some patients. In two related studies, Yale School of Medicine researchers examined one such driver, the EGF receptor, and found that a decoy receptor might be limiting the amount of drug that gets to the intended target.
› Verified 5 days ago
Gregory Vestal, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 570 Daniel Webster Hwy, Merrimack, NH 03054 Phone: 603-424-4519 | |
Stephen James Deminico, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 615 Daniel Webster Hwy, Merrimack, NH 03054 Phone: 603-423-9330 Fax: 603-423-9336 | |
Lauren Herrick West, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 570 Daniel Webster Hwy, Merrimack, NH 03054 Phone: 603-424-4519 | |
Renan Moretta, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 416 Daniel Webster Hwy, Merrimack, NH 03054 Phone: 603-424-4833 Fax: 603-424-4578 | |
Mr. Brad A Valenti, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 7 Continental Blvd, Merrimack, NH 03054 Phone: 603-429-0759 Fax: 603-429-0813 | |
Dr. Meghan Armstrong, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 456 Daniel Webster Hwy, Merrimack, NH 03054 Phone: 603-424-1120 | |
Nancy Delaney, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 456 Daniel Webster Hwy, Merrimack, NH 03054 Phone: 603-424-1120 |